Literature DB >> 25204206

Intralesional bleomycin injection in management of low flow vascular malformations in children.

Anita T Mohan1, Saleigh Adams, Kevin Adams, Donald A Hudson.   

Abstract

Low flow vascular malformations are challenging to manage, particularly with their propensity to grow, and can lead to severe disfigurement and dysfunction. Traditional surgical excision is fraught with tedious dissection and complications, particularly in the head and neck region. Trends toward less invasive techniques, such as intralesional sclerotherapy, are proving to be successful independent treatments or adjuncts in management in low flow vascular malformations. This study was a retrospective case note review, over an 8-year period, reporting the outcomes of 32 children (mean = 5.8 years, range = 5 months-11.5 years) with radiologically confirmed low flow vascular malformations, treated with serial intralesional bleomycin injection (IBI) therapy. Patient demographics, lesion characteristics, imaging findings, treatment course, radiological and clinical response to treatment were recorded. An overall 91% (n = 29) response rate was achieved, with 28% obtaining complete resolution for low flow vascular malformations. Lesions were sub-categorized into venous malformation, including mixed venous-capillary (n = 27) or lymphatic malformation (LM) (n = 5). Twenty-seven of 32 children experienced no complications. Local complications included superficial skin infection (n = 2), skin necrosis (n = 1), hyperpigmentation, and minor contour deformity. There was no recurrence and no systemic side-effects to bleomycin. Mean follow-up was 38 months (range = 6-95 months). In conclusion, serial intralesional bleomycin injections can be effective and also safe in a paediatric population for the successful management of symptomatic or disfiguring low flow vascular malformations.

Entities:  

Keywords:  Low flow vascular malformations; intralesional bleomycin; lymphatic malformations; paediatric vascular malformations; sclerotherapy; venous malformations

Mesh:

Substances:

Year:  2014        PMID: 25204206     DOI: 10.3109/2000656X.2014.951051

Source DB:  PubMed          Journal:  J Plast Surg Hand Surg        ISSN: 2000-6764


  6 in total

1.  Vitamin C increases DNA breaks and suppresses DNA damage-independent activation of ATM by bleomycin.

Authors:  Blazej Rubis; Michal W Luczak; Casey Krawic; Anatoly Zhitkovich
Journal:  Free Radic Biol Med       Date:  2019-03-26       Impact factor: 7.376

Review 2.  MRI of the Central Lymphatic System: Indications, Imaging Technique, and Pre-Procedural Planning.

Authors:  Vishwan Pamarthi; Waleska M Pabon-Ramos; Vincent Marnell; Lynne M Hurwitz
Journal:  Top Magn Reson Imaging       Date:  2017-08

Review 3.  Recent Progress in Lymphangioma.

Authors:  Xiaowei Liu; Cheng Cheng; Kai Chen; Yeming Wu; Zhixiang Wu
Journal:  Front Pediatr       Date:  2021-12-15       Impact factor: 3.418

4.  Aqueous intralesional bleomycin sclerotherapy in lymphatic malformation: Our experience with children and adult.

Authors:  Ankur Bhatnagar; Vijai Datta Upadhyaya; Basant Kumar; Zafar Neyaz; Ajay Kushwaha
Journal:  Natl J Maxillofac Surg       Date:  2017 Jul-Dec

5.  Chitosan-based liposomal thermogels for the controlled delivery of pingyangmycin: design, optimization and in vitro and in vivo studies.

Authors:  Ling Zhang; Fen Chen; Jiatong Zheng; Hongwei Wang; Xingjun Qin; Weisan Pan
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

6.  Lymphatic malformations in children: treatment outcomes of sclerotherapy in a large cohort.

Authors:  Frédérique C M Bouwman; Silje S Kooijman; Bas H Verhoeven; Leo J Schultze Kool; Carine J M van der Vleuten; Sanne M B I Botden; Ivo de Blaauw
Journal:  Eur J Pediatr       Date:  2020-10-13       Impact factor: 3.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.